Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMFAZLU)

Drug Name
AZD6280 Drug Info
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Discontinued in Phase 1 [1]
Schizophrenia 6A20 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
23630026
CAS Number
CAS 942436-93-3
TTD Drug ID
DMFAZLU

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-3 (GABRA3) TT37EDJ GBRA3_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
GABA(A) receptor alpha-3 (GABRA3) DTT GABRA3 1.722 2.511 1.585 2.485
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 06 Mental, behavioural or neurodevelopmental disorder
Disease Class ICD-11: 6A20 Schizophrenia
The Studied Tissue Pre-frontal cortex
The Studied Disease Schizophrenia [ICD-11:6A20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
GABA(A) receptor alpha-3 (GABRA3) DTT GABRA3 6.05E-02 -0.26 -0.27
GABA(A) receptor alpha-3 (GABRA3) DTT GABRA3 9.54E-01 -0.14 -0.36
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027607)
2 AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33.